Rob Brierley
LightNews LightNews
banner
robbrierley.bsky.social
Rob Brierley
@robbrierley.bsky.social
1.3K followers 520 following 290 posts
Editor-in-Chief, The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social.

Views my own; reposting ≠ endorsement. #GastroSky #LiverSky #GISky #OncSky
Posts Replies Media Videos
robbrierley.bsky.social
I'll be at #UEGWeek in Berlin October 5-7! If you'd like to discuss your research or ideas for reviews or opinion pieces, or just catch up over a coffee, please drop me a line!

#gastroenterology #UEGWeek2025
September 29, 2025 at 6:50 AM
robbrierley.bsky.social
New @lancetgastrohep.bsky.social

Non-inferiority of lyophilised faecal filtrate vs lyophilised donor stool was not established for the prevention of C difficile recurrence over 8 weeks

👉 Live 🦠 crucial in mediating clinical efficacy

www.thelancet.com/journals/lan...

#GISky #IDSky #MicroSky #FMT
September 23, 2025 at 1:13 PM
robbrierley.bsky.social
It’s that time of year…

#EngvInd
July 31, 2025 at 1:59 PM
robbrierley.bsky.social
It's that time of the year when journal metrics are updated...

Thanks, as ever, to our authors, peer reviewers, advisory board, & colleagues, who enable us to continue publishing work that changes the lives of those living with digestive diseases.

#GastroSky #MedSky @lancetgastrohep.bsky.social
June 18, 2025 at 8:39 AM
robbrierley.bsky.social
New @jama.com - Screening colonoscopy yields among adults aged 45–49 years after lowering the colon cancer screening age

jamanetwork.com/journals/jam...

#GastroSky #OncSky #MedSky @oncoalert.bsky.social
June 11, 2025 at 2:08 PM
robbrierley.bsky.social
After 3 years of upadacitinib, >50% of patients were in clinical remission at wk 96 (74–76% of patients in the as-observed analyses, 55–59% in the modified non-responder imputation analysis)

Safety was consistent with previous analyses; details in screenshot below

#gastrosky #medsky #ibdsky
May 9, 2025 at 10:45 AM
robbrierley.bsky.social
COPE (Committee on Publication Ethics) statement on external influence on editorial decisions

publicationethics.org/news-opinion...

#Medsky
May 2, 2025 at 10:56 AM
robbrierley.bsky.social
New Comment in @thelancetoncol.bsky.social - A new war on cancer?

www.thelancet.com/journals/lan...

#OncSky #MedSky @oncoalert.bsky.social
March 19, 2025 at 1:21 PM
robbrierley.bsky.social
New at @thelancetoncol.bsky.social - the SANO phase 3 trial - Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer
www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky @oncoalert.bsky.social
March 18, 2025 at 1:34 PM
robbrierley.bsky.social
New @thelancet.bsky.social Editorial - American chaos: standing up for health and medicine

www.thelancet.com/journals/lan...

#MedSky #GastroSky
February 6, 2025 at 9:54 AM
robbrierley.bsky.social
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

www.thelancet.com/journals/lan...

@thelancet.bsky.social

#GastroSky #MedSky #ASCOGI #OncSky @oncoalert.bsky.social
January 26, 2025 at 9:47 AM
robbrierley.bsky.social
Thermal ablation vs surgical resection of small colorectal liver metastases (COLLISION trial)

“The assumption that thermal ablation should be reserved for unresectable colorectal liver mets requires re-evaluation”

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky @oncoalert.bsky.social
January 21, 2025 at 8:26 AM
robbrierley.bsky.social
New research - Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis

www.thelancet.com/journals/lan...

#GastroSky #MedSky
January 17, 2025 at 8:09 AM
robbrierley.bsky.social
New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky @oncoalert.bsky.social
January 15, 2025 at 6:07 AM
robbrierley.bsky.social
Psychosocial impacts associated with GRAIL, a multicancer early detection test

New data on patient-reported outcomes at 12 months from the PATHFINDER study

www.thelancet.com/journals/lan...

#GastroSky #MedSky #OncSky @oncoalert.bsky.social
January 14, 2025 at 2:49 PM
robbrierley.bsky.social
Our latest issue is out today at www.thelancet.com/gastrohep

The issue features content on early-onset colorectal cancer, MASLD, Crohn’s disease, hepatic surgery, microbiome testing, viral hepatitis + more!

#GastroSky #LiverSky #OncSky #MedSky #MicroSky #IDSky
January 11, 2025 at 6:40 AM
robbrierley.bsky.social
New research - TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

www.thelancet.com/journals/lan...

@thelancet.bsky.social #MedSky #OncSky #LiverSky
January 9, 2025 at 8:09 AM
robbrierley.bsky.social
New research - Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

www.thelancet.com/journals/lan...

@thelancet.bsky.social #LiverSky #OncSky #MedSky
January 9, 2025 at 8:07 AM
robbrierley.bsky.social
New research - Sands et al - Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial

https://buff.ly/3BW2ZWh

#IBDSky #GastroSky #MedSky
January 8, 2025 at 3:02 AM
robbrierley.bsky.social
New research - Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

www.thelancet.com/journals/lan...

#OncSky #GastroSky #MedSky
January 7, 2025 at 8:04 AM
robbrierley.bsky.social
New research - Atia et al - Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study

https://buff.ly/427D74B

#IBDSky #GastroSky #MedSky
January 7, 2025 at 5:06 AM
robbrierley.bsky.social
A two-part Series explored the current outlook and future of microbiome-based therapeutics, with a deeper dive into their role in inflammatory bowel disease

www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...

#GISky #MedSky #MicroSky #IBDSky
December 20, 2024 at 9:14 AM
robbrierley.bsky.social
We charted progress towards the elimination of viral hepatitis in the second Lancet Gastroenterology & Hepatology Commission on viral hepatitis

www.thelancet.com/journals/lan...

#MedSky #LiverSky #IDSky #HepSky
December 20, 2024 at 9:03 AM
robbrierley.bsky.social
How much of a role does expectancy of gluten intake have in symptoms of non-coeliac gluten sensitivity?

An RCT probed the role of the nocebo effect in this condition - www.thelancet.com/journals/lan...

#MedSky #GastroSky
December 20, 2024 at 8:57 AM
robbrierley.bsky.social
We're closing out the year with our annual editors' selection of highlights from The Lancet Gastroenterology & Hepatology

Follow the🧵below!

#GastroSky #LiverSky #MedSky
December 20, 2024 at 8:56 AM